Das Nagoya-Protokoll

Zusammenfassung

Das Nagoya-Protokoll ist ein bindender, transnationaler Vertrag, der unter der Berücksichtigung des Schutzes der Biodiversität einen gerechten Vorteilsausgleich für die Nutzung genetischer Ressourcen, wie z. B. Pflanzen zur Arzneimittel-herstellung sicherstellen soll. Aufgrund der enormen Vielfalt nehmen Pflanzen eine signifikante Rolle für die Erforschung neuer pharmazeutischer Wirkstoffe ein. Vor diesem Hintergrund sowie der Vielschichtigkeit des Nagoya-Protokolls ist die nähere Betrachtung der rechtlichen Vorgaben sowohl für Hersteller als auch für nicht-kommerzielle Forschungseinrichtungen von großer Bedeutung.

Abstract

The Nagoya Protocol: Importance and Influence on Manufactures of Plant-based Medicinal Products and Non-commercial Research Institutions

The Nagoya Protocol is a binding transnational contract, which ensures a fair balance of benefits from the usage of genetic resources e. g. plants for medical production under the protection of biodiversity. Based on the large diversity, plants play a key role in the research on new pharmaceutical substances. Against this background and the complexity of the Nagoya Protocol, a closer consideration of legal requirements has a major value for manufacturers as well as for non-commercial research institutions.

• Literatur

• 1 Amtsblatt der Europäischen Union. Verordnung (EU) Nr. 511 / 2014 des Europäischen Parlaments und des Rates über Maßnahmen für die Nutzer zur Einhaltung der Vorschriften des Protokolls von Nagoya über den Zugang zu genetischen Ressourcen und die ausgewogene und gerechte Aufteilung der sich aus ihrer Nutzung ergebenden Vorteile in der Union vom 16. April 2014
• 2 Buck M, Hamilton C. The Nagoya Protocol on access to genetic resources and the fair and equitable sharing of benefits arising from their utilization to the convention on biological diversity. Reciel 2011; 20: 47-61. doi: 10.1111/j.1467-9388.2011.00703.x
• 3 Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). Statistiken – Besondere Therapierichtungen und Traditionelle Arzneimittel 2019. https: //www.bfarm.de/DE/Service/Statistiken/AM_statistik/Besondere_Therapierichtungen_statistik/_node.html
• 4 Calixto JB. The role of natural products in modern drug discovery. An Acad Bras Cienc 2019; 91 (Suppl. 3): e20190105.
• 5 Convention on Biological Diversity. CBD – the First Years. https://www.cbd.int/doc/publications/CBD-the-first-years.pdf
• 6 Convention on Biological Diversity. Bioscience at a Crossroads. Access and Benefit Sharing in a Time of Scientific, Technological and Industry Change: The Food and Beverage Sector. 2013
• 7 Convention on Biological Diversity. Report of the meeting of the group of legal and technical experts on concepts, terms, working definitions and sectoral approaches. 2008
• 8 Convention on Biological Diversity. Issues for consideration in the establishment of the access and benefit-sharing clearing-house. 2011 https://www.cbd.int/doc/meetings/abs/emabschm-01/official/emabschm-01-02-en.pdf
• 9 Department Environmental Affairs Republic of South Africa. Group of Like-Minded Megadiverse Countries (LMMC). https://www.environment.gov.za/likeminded_megadiversecountries_lmmc
• 10 Djoghlaf A. Der Bonner Gipfel für die Biologische Vielfalt: Geburtsstätte einer Globalen Allianz für das Leben dieser Erde. 2008 https://www.cbd.int/doc/speech/2008/sp-2008-05-naturallianz-de.pdf
• 11 Earth Negotiations Bulletin – IISD Reporting Services. Summary of the fourth meeting of the working group on access and benefit-sharing of the convention on biological diversity 30 January – 3 February 2006. IISD 2006. https://enb.iisd.org/download/pdf/enb09344e.pdf
• 12 Earth Negotiations Bulletin – IISD Reporting Services. Summary of the ninth conference of the parties to the convention on biological diversity: 19-20 May 2008. IISD 2008. https://enb.iisd.org/download/pdf/enb09452e.pdf
• 13 Earth Negotiations Bulletin – IISD Reporting Services. Summary of the tenth conference of the parties to the convention on biological diversity 18-29 October 2010. IISD 2010. https://enb.iisd.org/download/pdf/enb09544e.pdf
• 14 European Commission. Commission notice Guidance document on the scope of application and core obligations of Regulation (EU) No 511 / 2014 of the European Parliament and of the Council on the compliance measures for users from the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilisation in the Union. 27. August 2016. Official Journal of the EU C313 / 1
• 15 Fodella A. Recent developments on access and benefit sharing relating to genetic resources (ABS) in international law. Universität Trient 2014
• 16 Food and Agriculture Organization. Resolution 8 / 83 International undertaking on Plant Genetic Resources. 1983 http://www.fao.org/wiews-archive/docs/Resolution_8_83.pdf
• 17 Greenwell M, Rahman PK. Medicinal plants: Their use in anticancer treatment. Int J Pharm Sci Res 2015; 6: 4103-4112. doi: 10.13040/IJPSR.0975-8232.6(10).4103-12
• 18 Hardison P. Prior Informed Consent (PIC) Prior Informed Approval (PIA) PartI. 2000 https://trade.ec.europa.eu/doclib/docs/2005/april/tradoc_122179.pdf
• 19 Mazor T, Doropoulos C, Schwarzmueller F. et al. Global mismatch of policy and research on drivers of biodiversity loss. Nat Ecol Evol 2018; 2: 1071-1074. doi: 10.1038/s41559-018-0563-x
• 20 McGraw DM. The CBD – key characteristics and implications for implementation. Reciel 2002; 11: 17-28. doi: 10.1111/1467-9388.00299
• 21 Morgera E, Tsioumani E, Buck M. Unraveling the Nagoya Protocol - A Commentary on the Nagoya Protocol on Access and Benefit-sharing to the Convention on Biological Diversity. Leiden: Brill | Nijhoff; 2014
• 22 Neergheen-Bhujun V, Awan AT, Baran Y. et al. Biodiversity, drug discovery, and the future of global health: Introducing the biodiversity to biomedicine consortium, a call to action. J Glob Health 2017; 7: 020304. doi: 10.7189/jogh.07.020304
• 23 Rourke MF. Access and benefit-sharing in practice: non-commercial research scientists face legal obstacles to accessing genetic resources. J Sci Policy Governance – JSPG 2018: Vol. 13 https://www.sciencepolicyjournal.org/uploads/5/4/3/4/5434385/rourke.pdf
• 24 Secretariat of the Convention on Biological Diversity. Bonn guidelines on access to genetic resources and fair and equitable sharing of the benefits arising out of their utilization. 2002
• 25 Secretariat of the Convention on Biological Diversity. Nagoya Protocol Access to genetic resources and the fair and equitable Sharing of benefits arising from their utilization to the Convention on Biological Diversity. 2011 https://www.cbd.int/abs/doc/protocol/nagoya-protocol-en.pdf
• 26 Sturn BS. Die neunte Vertragsstaatenkonferenz des Übereinkommens über die biologische Vielfalt (COP9 / CBD) als Diskursarena im Diskursfeld „Klimabedingte Veränderungen der Biodiversität“. 2009 http://www.isoe-publikationen.de/fileadmin/redaktion/ISOE-Reihen/msoe/msoe-28-isoe-2009.pdf
• 27 Teixeira I. Statement by H.E. Ms. Izabella Teixeira, Minister of the Environment of Brazil, on behalf of the Group of Like-Minded Megadiverse Countries at the panel discussion on “The way forward in achieving the three objectives of the CBD, and the internationally agreed biodiversity goals and targets”. 2010 https://www.cbd.int/doc/strategic-plan/unga-hlm/statements/Megadiverse_Countries.pdf
• 28 The Access and Benefit-Sharing Clearing-House. https://absch.cbd.int/
• 29 United Nations. Convention on Biological Diversity. 1992 https://www.cbd.int/doc/legal/cbd-en.pdf
• 30 UN Environmental Program. Megadiverse Countries. https://www.biodiversitya-z.org/content/megadiverse-countries
• 31 Veeresham C. Natural products derived from plants as a source of drugs. J Adv Pharm Technol Res 2012; 3: 200-201. doi: 10.4103/2231-4040.104709
• 32 WWF. How many species are we losing? https://wwf.panda.org/our_work/biodiversity/biodiversity/
• 33 https://www.bfn.de/fileadmin/ABS/documents/ABS_Dokumente_ab_September_2015/20170322_Handlungsempfehlungen_01.pdf
• 34 http://www.swedishepa.se/Environmental-objectives-and-cooperation/Swedish-environmental-work/Work-areas/the-nagoya-protocol/
• 35 https://cetaf.org/news/european-commission-recognition-cetaf-code-conduct-and-best-practice-access-and-benefit-sharing
• 36 Waimer F, Torres-Londono P, Stekly G. et al. Implementation of the Nagoya Protocol. Pharmind 2018; 80 (12) : 1662-1667. http: //www.pharmind.eu/beitrag/pharmind/Implementation_of_the_Nagoya_Protocol